Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
A method and system for modulating an individual's microbiome in a manner such that individuals who are overweight, obese and/or suffer from cardiometabolic diseases and/or inflammatory bowel diseases are able to reduce the incidence of chronic conditions and diseases associated therewith. Certain embodiments are directed to a method and bacterial formulations for reducing the likelihood of developing NAFLD and NASH.
1. A method for reducing the likelihood of developing non-alcoholic fatty liver disease, comprising: providing to an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species; administering at least 6 grams per day of fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual; and inhibiting monoacylglycerolacyltransferase-3 (MGAT3) synthesis in the individual to lower triacylglycerol (TAG) production.
2. The method as set forth in claim 1 , wherein the beneficial bacteria are encapsulated in a frangible enclosure.
3. The method as set forth in claim 1 , further comprising inhibiting expression of diacylglycerolacyltransferase-2 (DGAT-2) in said individual.
4. The method as set forth in claim 1 , further comprising increasing the levels of Roseburia in the individual's gut microbiome.
5. The method as set forth in claim 4 , further comprising increasing the populations of at least two of the following in the individual's gut microbiome: Akkermansia muciniphila, Faecalibacterium prausnitzii, Bifidobacterium longum, Roseburia intestinalis.
6. A method for reducing the likelihood of non-alcoholic fatty liver disease, comprising: providing to an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species; administering at least 6 grams per day of fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual; inhibiting expression of diacylglycerolacyltransferase-2 (DGAT-2) in said individual; and increasing the levels of Roseburia in the individual's gut microbiome.
7. The method as set forth in claim 6 , further comprising increasing the populations of at least two of the following in the individual's gut microbiome: Akkermansia muciniphila, Faecalibacterium prausnitzii, Bifidobacterium longum, Roseburia intestinalis, Coprococcus spp. and Veillonella.
8. The method as set forth in claim 6 , wherein the beneficial bacteria are encapsulated in a frangible enclosure.
9. The method as set forth in claim 6 , wherein the population of beneficial bacteria include bacteria that have been modified using a clustered regularly interspaced short palindromic repeats (CRIPSR)-CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Franscisella 1 (Cpf1a) system.
10. The method as set forth in claim 6 , further comprising inhibiting monoacylglycerolacyltransferase-3 (MGAT3) synthesis in the individual to lower triacylglycerol (TAG) production.
11. A method for reducing the likelihood of developing non-alcoholic fatty liver disease, comprising: providing to an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species; administering at least 6 grams per day of fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual; and increasing the levels of at least two bacteria selected from the group consisting of Akkermansia muciniphila, Faecalibacterium prausnitzii, Bifidobacterium longum, Roseburia intestinalis , and Coprococcus in the individual's gut microbiome.
12. The method as set forth in claim 11 , wherein the beneficial bacteria are encapsulated in a frangible enclosure.
13. The method as set forth in claim 11 , further comprising inhibiting expression of diacylglycerolacyltransferase-2 (DGAT-2) in said individual.
14. The method as set forth in claim 11 , further comprising inhibiting monoacylglycerolacyltransferase-3 (MGAT3) synthesis in the individual to lower triacylglycerol (TAG) production.
15. The method as set forth in claim 11 , wherein a secretion of glucagon-like peptide-1 (GLP-1) is stimulated in the individual due to the production of butyrate by the administration of the at least two bacteria.
16. A method for reducing the likelihood of developing non-alcoholic fatty liver disease, comprising: providing to an individual through oral administration a population of beneficial bacteria that comprises bacteria selected from the group consisting of Akkermansia muciniphila, Faecalibacterium prausnitzii, Bifidobacterium longum, Roseburia intestinalis, Coprococcus spp. and Veillonella , wherein a secretion of glucagon-like peptide-1 (GLP-1) is stimulated in the individual due to the production of butyrate by the beneficial bacteria; wherein the beneficial bacteria are encapsulated in a frangible enclosure.
17. A method for reducing the likelihood of developing non-alcoholic fatty liver disease, comprising: providing to an individual through oral administration a population of beneficial bacteria that comprises bacteria selected from the group consisting of Akkermansia muciniphila, Faecalibacterium prausnitzii, Bifidobacterium longum, Roseburia intestinalis, Coprococcus spp. and Veillonella , wherein a secretion of glucagon-like peptide-1 (GLP-1) is stimulated in the individual due to the production of butyrate by the beneficial bacteria; further comprising inhibiting expression of diacylglycerolacyltransferase-2 (DGAT-2) in said individual.
18. A method for reducing the likelihood of developing non-alcoholic fatty liver disease, comprising: providing to an individual through oral administration a population of beneficial bacteria that comprises bacteria selected from the group consisting of Akkermansia muciniphila, Faecalibacterium prausnitzii, Bifidobacterium longum, Roseburia intestinalis, Coprococcus spp. and Veillonella , wherein a secretion of glucagon-like peptide-1 (GLP-1) is stimulated in the individual due to the production of butyrate by the beneficial bacteria; further comprising inhibiting monoacylglycerolacyltransferase-3 (MGAT3) synthesis in the individual to lower triacylglycerol (TAG) production.